Investor Presentaiton

Fully Accelerated Global Development Footprint Global Development Organization and Capability Building up fully functioned global development team in short time: Global study footprint Drive and execute global strategy Strong CRO and vendor oversight Interface regulatory interactions Support in global medical community Explore Pipeline with Global Potential Sintilimab: BLA for 1L nsqNSCLC accepted by the U.S. FDA in May 2021. Pursue global opportunities for sintilimab across tumor types. Lilly IBI-305 (bevacizumab): NDA filed in Indonesia; Out licensed north America rights to Coherus Coherus OSCIENCES IBI-188 (CD47): Phase 1b in China and US IBI-322 (PD-L1/CD47): Phase 1 in China and US IBI-110 (LAG-3): IND approved by US FDA IBI-939 (TIGIT): IND approved by US FDA etana Biotech Global Development Strategy Innovation: Globally develop innovative and transformative molecules in indications with high unmet medical need Differentiation: Find differentiation position for innovative molecules by tumor/disease type, disease setting and mechanism of action Globalization: Build global development platform, team, and establish global clinical monitoring capabilities Innovent Leverage the advantages of China clinical development to accelerate pipeline's global development and registration. Innovent Expand overseas talent team as to fit the increasing global operation needs. Confidential Copyright©2021 Innovent Biologics 40 40

View entire presentation